COMP <GO>
XFOR vs SCTX // RETURN ON INVESTED CAPITAL (ROIC)
X4 Pharmaceuticals Inc. (NASDAQ) VS. Scribe Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: XFOR 2
— SCTX 0
■ METRIC PARITY
LAST: $3.36 (+0.30%) • MKT CAP: $333.1M
roic
-35.00%
LAST: $17.44 (-0.57%) • MKT CAP: $330.2M
roic
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (XFOR VS. SCTX)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | XFOR | SCTX | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 83.60% | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | — | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | — | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 180.00% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | — | — | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 60.3 | 36.8 | +23.57 | XFOR | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $333.1M | $330.2M | $3.0M | XFOR | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | XFOR REV | SCTX REV | XFOR GROSS % | SCTX GROSS % | XFOR FCF | SCTX FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $35.1M | $0 | 83.6% | — | -$85.6M | — |
| FY 2024 | $2.6M | — | 68.8% | — | -$131.2M | — |
| FY 2023 | $0 | — | — | — | -$96.5M | — |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
XFOR // BETA —
SCTX // BETA —